Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
复制标题
DOI：
10.1183/09031936.00125812
复制
发表时间：
2013-06
期刊：
影响因子：
--
通讯作者：
Wells CD
中科院分区：
文献类型：
--
作者：
Skripconoka V;Danilovits M;Pehme L;Tomson T;Skenders G;Kummik T;Cirule A;Leimane V;Kurve A;Levina K;Geiter LJ;Manissero D;Wells CD
Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease. Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes. Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable. Delamanid treatment groups were combined for analysis, based on their duration of treatment. In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments. Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months. Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001). Treatment benefit was also seen among patients with extensively drug-resistant TB. This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.
登录
查看更多内容
OPC-67683，一种硝基二氢 - 米达佐尔衍生物，在体外和小鼠中针对结核病有前途的作用。
影响因子：
15.8
作者：
Matsumoto, Makoto;Hashizume, Hiroyuki;Tomishige, Tatsuo;Kawasaki, Masanori;Tsubouchi, Hidetsugu;Sasaki, Hirofumi;Shimokawa, Yoshihiko;Komatsu, Makoto
通讯作者：
Komatsu, Makoto
影响因子：
24.3
作者：
Migliori, G. B.;Lange, C.;Cirillo, D. M.
通讯作者：
Cirillo, D. M.
DOI：
10.1086/653115
发表时间：
2010-07-01
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Jacobson KR;Tierney DB;Jeon CY;Mitnick CD;Murray MB
通讯作者：
Murray MB
DOI：
10.5588/ijtld.10.0616
发表时间：
2011-07-01
影响因子：
4
作者：
Diacon, A. H.;Dawson, R.;Donald, P. R.
通讯作者：
Donald, P. R.
欧盟国家的结核病治疗结果监测：系统评价。
DOI：
10.1183/09031936.00030612
发表时间：
2013-03
期刊：
The European respiratory journal
影响因子：
--
作者：
van Hest R;Ködmön C;Verver S;Erkens CG;Straetemans M;Manissero D;de Vries G
通讯作者：
de Vries G